5 citations
,
May 2020 in “Clinical and Experimental Dermatology” Clascoterone may be a promising treatment for hair loss.
November 2015 in “Journal of the Korea Academia-Industrial cooperation Society” The new assay can help develop products for hair re-growth.
12 citations
,
September 2018 in “Dermatologic Therapy” Daily low-dose aspirin lowers minoxidil's effectiveness for hair loss treatment.
May 2019 in “Clinica chimica acta” The study developed methods to measure biomarkers in mice and found differences in hormone levels linked to gut microbiota diversity and stress response.
37 citations
,
April 1979 in “The Journal of Clinical Pharmacology” Minoxidil effectively controls blood pressure but side effects may limit its use.
19 citations
,
July 1990 in “Cleveland Clinic journal of medicine” Androgen excess disorders in women were effectively treated with spironolactone, estrogen, and dexamethasone.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
2 citations
,
August 2024 in “JAAD International” Combining low-dose oral minoxidil and spironolactone may improve hair growth safely.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
2 citations
,
November 2017 in “Elsevier eBooks” Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.
April 2016 in “Journal of The American Academy of Dermatology” Some blood pressure medications are linked to a higher risk of skin cancer.
August 1993 in “Journal of Dermatological Science” Cyclosporin and minoxidil promote hair growth.
December 2023 in “Farmateka” Minoxidil is an effective and safe treatment for common hair loss when applied to the skin, but more research is needed for optimal use.
September 2024 in “Archives of Dermatological Research” Both treatment combinations improved hair growth similarly and were safe.
October 2025 in “Journal of Molecular Structure” Hyaluronic acid microneedles help deliver minoxidil derivatives effectively for hair regrowth.
Neurosteroids help control dopamine responses in the brain.
1 citations
,
January 1989 in “Handbook of experimental pharmacology” Anti-androgens can help reduce the effects of male hormones on the skin.
2 citations
,
January 1986 in “PubMed” Spironolactone improved symptoms in women with hormonal imbalances and had few side effects.
Low-dose oral minoxidil can cause dry mouth.
1 citations
,
January 2003 in “Expert Opinion on Therapeutic Patents” Steroid sulfatase inhibitors could potentially treat hormone-related disorders like certain cancers, hair loss, acne, and improve cognitive dysfunction.
3 citations
,
December 2000 in “PubMed” CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.
8 citations
,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
8 citations
,
August 2020 in “Clinical and Experimental Dermatology” Spironolactone is a low-cost, effective, and generally safe treatment for various skin conditions related to hormones.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
18 citations
,
January 1976 in “Clinical Science” Minoxidil effectively lowers severe high blood pressure but may cause side effects like increased hair growth.
April 1992 in “Current opinion in therapeutic patents” New steroids were patented as effective for treating acne, hair loss, and other conditions related to hormones.
1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
January 2026 in “Mendeley Data” January 2026 in “Mendeley Data”